Cargando…

Dyslipidemia Diagnosis and Treatment: Risk Stratification in Children and Adolescents

Dyslipidemias or dyslipoproteinemias are quantitative changes in total cholesterol concentration, respective fractions, or triglycerides in the plasma. Evidence supported that dyslipidemia in childhood is associated with atherosclerosis in adulthood, and early identification and treatment potentiall...

Descripción completa

Detalles Bibliográficos
Autores principales: Mosca, Sara, Araújo, Graça, Costa, Vanessa, Correia, Joana, Bandeira, Anabela, Martins, Esmeralda, Mansilha, Helena, Tavares, Mónica, Coelho, Margarida P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885266/
https://www.ncbi.nlm.nih.gov/pubmed/35237450
http://dx.doi.org/10.1155/2022/4782344
_version_ 1784660373838757888
author Mosca, Sara
Araújo, Graça
Costa, Vanessa
Correia, Joana
Bandeira, Anabela
Martins, Esmeralda
Mansilha, Helena
Tavares, Mónica
Coelho, Margarida P.
author_facet Mosca, Sara
Araújo, Graça
Costa, Vanessa
Correia, Joana
Bandeira, Anabela
Martins, Esmeralda
Mansilha, Helena
Tavares, Mónica
Coelho, Margarida P.
author_sort Mosca, Sara
collection PubMed
description Dyslipidemias or dyslipoproteinemias are quantitative changes in total cholesterol concentration, respective fractions, or triglycerides in the plasma. Evidence supported that dyslipidemia in childhood is associated with atherosclerosis in adulthood, and early identification and treatment potentially reduce cardiovascular risk in adulthood, which is the principal cause of morbidity and mortality in developed countries. Dyslipidemias can result from primary lipoprotein metabolism changes due to different genetic causes (primary dyslipidemias) or as a consequence of exogenous factors or other pathologies (secondary dyslipidemias). Therefore, the combined dyslipidemias result from the association of important epigenetic and environmental influences with risk factors for cardiovascular disease. The criterion for lipid metabolism screening at young ages is not widely accepted and possibly follows a universal or directed screening strategy. Additionally, little is known about its long-term effects or possible risk-benefit despite the growing tendency to start pharmacological therapy. Therefore, this study aimed to review the available bibliography on dyslipidemia in pediatric age to present a practical and structured approach to dyslipidemia that focuses on screening, risk stratification for atherosclerotic disease, and therapeutic approach.
format Online
Article
Text
id pubmed-8885266
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-88852662022-03-01 Dyslipidemia Diagnosis and Treatment: Risk Stratification in Children and Adolescents Mosca, Sara Araújo, Graça Costa, Vanessa Correia, Joana Bandeira, Anabela Martins, Esmeralda Mansilha, Helena Tavares, Mónica Coelho, Margarida P. J Nutr Metab Review Article Dyslipidemias or dyslipoproteinemias are quantitative changes in total cholesterol concentration, respective fractions, or triglycerides in the plasma. Evidence supported that dyslipidemia in childhood is associated with atherosclerosis in adulthood, and early identification and treatment potentially reduce cardiovascular risk in adulthood, which is the principal cause of morbidity and mortality in developed countries. Dyslipidemias can result from primary lipoprotein metabolism changes due to different genetic causes (primary dyslipidemias) or as a consequence of exogenous factors or other pathologies (secondary dyslipidemias). Therefore, the combined dyslipidemias result from the association of important epigenetic and environmental influences with risk factors for cardiovascular disease. The criterion for lipid metabolism screening at young ages is not widely accepted and possibly follows a universal or directed screening strategy. Additionally, little is known about its long-term effects or possible risk-benefit despite the growing tendency to start pharmacological therapy. Therefore, this study aimed to review the available bibliography on dyslipidemia in pediatric age to present a practical and structured approach to dyslipidemia that focuses on screening, risk stratification for atherosclerotic disease, and therapeutic approach. Hindawi 2022-02-21 /pmc/articles/PMC8885266/ /pubmed/35237450 http://dx.doi.org/10.1155/2022/4782344 Text en Copyright © 2022 Sara Mosca et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Mosca, Sara
Araújo, Graça
Costa, Vanessa
Correia, Joana
Bandeira, Anabela
Martins, Esmeralda
Mansilha, Helena
Tavares, Mónica
Coelho, Margarida P.
Dyslipidemia Diagnosis and Treatment: Risk Stratification in Children and Adolescents
title Dyslipidemia Diagnosis and Treatment: Risk Stratification in Children and Adolescents
title_full Dyslipidemia Diagnosis and Treatment: Risk Stratification in Children and Adolescents
title_fullStr Dyslipidemia Diagnosis and Treatment: Risk Stratification in Children and Adolescents
title_full_unstemmed Dyslipidemia Diagnosis and Treatment: Risk Stratification in Children and Adolescents
title_short Dyslipidemia Diagnosis and Treatment: Risk Stratification in Children and Adolescents
title_sort dyslipidemia diagnosis and treatment: risk stratification in children and adolescents
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885266/
https://www.ncbi.nlm.nih.gov/pubmed/35237450
http://dx.doi.org/10.1155/2022/4782344
work_keys_str_mv AT moscasara dyslipidemiadiagnosisandtreatmentriskstratificationinchildrenandadolescents
AT araujograca dyslipidemiadiagnosisandtreatmentriskstratificationinchildrenandadolescents
AT costavanessa dyslipidemiadiagnosisandtreatmentriskstratificationinchildrenandadolescents
AT correiajoana dyslipidemiadiagnosisandtreatmentriskstratificationinchildrenandadolescents
AT bandeiraanabela dyslipidemiadiagnosisandtreatmentriskstratificationinchildrenandadolescents
AT martinsesmeralda dyslipidemiadiagnosisandtreatmentriskstratificationinchildrenandadolescents
AT mansilhahelena dyslipidemiadiagnosisandtreatmentriskstratificationinchildrenandadolescents
AT tavaresmonica dyslipidemiadiagnosisandtreatmentriskstratificationinchildrenandadolescents
AT coelhomargaridap dyslipidemiadiagnosisandtreatmentriskstratificationinchildrenandadolescents